Opsona Therapeutics
From Wikipedia, the free encyclopedia
 | |
| Founded | 1 January 2004  |
|---|---|
| Headquarters | , Republic of Ireland |
| Website | www |
Opsona Therapeutics was a drug development company specialising in the human immune system and new drugs and vaccines to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases.[1][2][3]
Based in Ireland, Opsona was a spin-out from Trinity College Dublin (TCD).[4] Ireland is ranked highly in the world in immunology research, and TCD has been at the forefront of the field.[5]
Opsona's research was primarily focused on the role of Toll-like receptors (TLRs) and TLR signalling in human innate immunity. The company was founded in 2004 by three immunologists:
- Professor Luke O'Neill[6]
- Professor Kingston Mills[7]
- Professor Dermot P. Kelleher[8]
The company went into liquidation in 2019 after unsuccessful clinical trials, and failure to find a buyer for OPN-305.
Opsona's main investors were international and life-science focused:
- Inventages Venture Capital (Bahamas)[9]
- Seroba Bioventures (Ireland)
- GenenFund (United States)
- Enterprise Ireland (Ireland)[10]